ProKidney to acquire manufacturing facility in North Carolina for REACT commercial production

TAGS

ProKidney, a late clinical-stage cellular therapeutics company, has announced plans to acquire a 210,000 square foot facility and approximately 22 acres of land in Greensboro, North Carolina.

The move is aimed at meeting the company’s future commercial manufacturing needs for REACT, a renal autologous cell therapy currently in Phase 3 development for treating diabetic (CKD).

The transaction, valued at roughly $25.5 million, is set to close by June 2023, given standard closing conditions are met. Further investments are planned in the facility until 2028 in anticipation of potential commercial-scale production.

In alignment with the purchase agreement, has been granted an incentive package approved by the city of Greensboro, , and the North Carolina State Economic Investment Committee.

See also  Prevacus partners with Blinktbi for advanced concussion drug trials

The company is eligible to receive up to $13.3 million in tax credits, contingent on the fulfilment of specific milestones. These include creating at least 330 new jobs by the end of December 2028, and an investment of approximately $458 million in real and personal property by the end of December 2027.

Dr Tim Bertram — ProKidney CEO said: “This purchase represents an important component of our strategic manufacturing buildout.

“With a staged investment strategy based on the clinical trial success of REACT, potential regulatory approval, and ultimately commercial demand, if approved, we intend, along with our current Winston-Salem facility, to supply enough REACT to match initial commercial demand.

See also  Neuren Pharmaceuticals advances NNZ-2591 for Phelan-McDermid syndrome to Phase 3 clinical trial

“Subject to the outcome of the proact 1 and proact 2 , we are targeting a Biological Licensing Agreement submission for Food and Drug Administration approval of REACT in 2026.”

Anticipating approval, a subsequent commercial launch in the US by the company is expected later in the same year. With these timelines as a guide, ProKidney is gearing up its infrastructure to potentially transition into a commercial entity, said Dr Tim Bertram.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This